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ABSTRACT 
 
Introduction: Guillain-Barre syndrome (GBS) is a well known entity that has many infectious agents 
reported as antecedent events. The spectrum of GBS includes acute inflammatory demyelinating 
polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor sensory axonal 
neuropathy (AMSAN), and some other variants like Miller-Fisher syndrome (MFS).  
Methods: Patient with AMAN variant of GBS after severe bilateral pneumonia and ARDS due to the 
novel pandemic H1N1 influenza A virus is presented. 
Results: 28-year old white female was admitted to our Intensive Care Unit during the influenza 
pandemic because of severe ARDS due to bilateral pneumonia. The course of the disease was 
complicated with the new onset tetraplegia due to the AMAN variant of GBS. Treatment with plasma 
exchange was conducted and the patient had satisfactory recovery.  
Conclusion: We report a case of AMAN variant of GBS associated with proven H1N1 influenza A 
infection. This virus has not been reported previously as the agent of antecedent infection that induced 
this disorder. Risk factors for other causes of ICU neuromuscular weakness are usually present in the 
ICU patients and should not be the reason for reluctance in active quest for GBS. Once the diagnosis 
of GBS is established or suspected the treatment with plasma exchange or intravenous immune 
globulin is indicated. 
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INTRODUCTION 
 
 Guillain-Barre syndrome (GBS) is a well known entity that is characterized by acute flaccid 
paralysis. The spectrum of GBS includes classic, and the most common variant, acute inflammatory 
demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor sensory 
axonal neuropathy (AMSAN), and some other variants like Miller-Fisher syndrome (MFS).  
AMAN variant has clinical features similar to the classic AIDP and those include: ascending, 
symmetric paralysis of the extremities, loss of deep tendon reflexes and variable involvement of 
bulbar, respiratory, ocular and facial muscles as well as sensory symptoms. The most common 
antecedent event for AMAN is Campylobacter jejuni infection due to molecular mimicry between 
peripheral nerve components and lipo-oligosaccharide coat of Campylobacter [1]. However, some 
other agents like cytomegalovirus, Mycoplasma pneumoniae, Hemophilus influenzae and Epstein-Barr 
virus have been reported as triggers for this disorder as well [1,2,3]. Cerebrospinal fluid (CSF) 
analysis in AMAN variant of GBS usually reveals increased protein content with less than 50 cells per 
cubic millimeter as in AIDP. AMAN can be distinguished from other forms of GBS by 
electrophysiological studies and to some extent by anti-ganglioside antibody assay profile with GM1, 
GD1a, GD1b being positive and GQ1b negative [1]. Current treatment options include intravenous 
immune globulin (IVIG) and plasma exchange (PE). Outcome of AMAN is similar to the AIDP 
variant and approximately 80% of the patients recover fully or have minor deficits that do not interfere 
with every day activities [4]. Mortality traditionally approximated 5%, but a recent study in the US 
hospitals revealed mortality of only 2.58% [5].  
Pathogenesis of GBS is probably autoimmune with many infections and vaccines implicated 
as a triggering antecedent event. Seasonal influenza A and B have been serologically associated with 
GBS [6,7]. However, this association has been very scarce and has not been reported with the AMAN 
variant.  
 We present a case of AMAN variant of GBS after severe bilateral pneumonia and ARDS due 
to the novel pandemic H1N1 influenza A virus. Our patient presented as a new onset flaccid 
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tetraplegia after prolonged hospitalization in the ICU and the differential diagnosis of this condition in 
such clinical setting is discussed as well. 
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CASE REPORT 
 
In December of 2009 a previously healthy 28-year old white female was admitted to our 
Intensive Care Unit during the influenza pandemic because of severe ARDS due to bilateral 
pneumonia. She was not vaccinated with any influenza vaccine. The symptoms started 8 days prior to 
admission with fever, myalgia and cough. Shortness of breath begun a day before she was referred to 
our hospital. At admission she was febrile, normotensive, severely hypoxemic, fully alert with 
Glasgow coma score of 15. Crackles were present diffusely over both lungs. Remaining physical 
examination was unremarkable. Mechanical ventilation was started immediately after admission. 
Chest radiography revealed diffuse bilateral patchy infiltrates and tracheal aspirate detected genetic 
material of H1N1 influenza A by polymerase chain reaction. Due to the poor oxygenation despite the 
high level of conventional respiratory support extracorporeal membrane oxygenation (ECMO) was 
indicated. After seven days of ECMO treatment patient was weaned and after another three weeks 
there was no need for mechanical respiratory support. Muscle weakness was observed three days 
afterwards and evolved gradually over three days. At first this weakness was mistakenly attributed to 
the critical illness polyneropathy. Six days after the patient was weaned from the ventilator tetraplegia 
with areflexia was noticed. Weakness included equally proximal and distal muscles in all limbs 
without sensory symptoms and cranial nerve involvment. Spinal tap was performed and yielded CSF 
containing 1 cell per cubic millimeter with high protein content of 4.528 g/L.  
Electromyoneurography revealed reduced compound muscle action potential, fibrillation 
potentials in all examined muscles, F-waves were of mildly prolonged latency and conduction 
velocities were mildly reduced without the conduction block. Those features were indicative of motor 
axonal demage and compatible with AMAN. Semi-quantitative GanglioCombi ELISA anti-
ganglioside antibody assay was positive for GM1, GD1a and GD1b antibodies without the GQ1b 
antibody. However, this assay detects all anti-gangloside antibodies equally and cannot differentiate 
between the IgM and IgG subclasses. Furthermore, the results are listed as negative, grey zone, 
positive and strongly positive without the exact antibody titer. Computed tomography scan and the 
magnetic resonance imaging of the brain were normal. Plasma exchange commenced one day after the 
 8
detection of tetraplegia and complete treatment consisted of seven sessions. Over the period of 
approximately two months her muscle strength gradually recovered. Upper extremities are mildly 
paretic as well as the proximal muscles of the lower extremities. However, the distal muscles of the 
lower extremities are still severely affected and she is only able to perform flexion of the feet. At this 
time the patient is still recovering in our hospital.     
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DISCUSSION  
 
We report a case of AMAN variant of GBS associated with proven H1N1 influenza A 
infection. This virus has not been reported previously as the agent of antecedent infection that induced 
this disorder. Pandemic influenza in our patient presented as severe viral pneumonia and ARDS that 
required ECMO treatment and prolonged mechanical ventilation.  
Critically ill patients, such as the one presented, frequently acquire some form of 
neuromuscular weakness with the most common being critical illness myopathy (CIM) and critical 
illness polyneuropathy (CIP). Other causes of flaccid general weakness in the ICU population of 
patients are: prolonged neuromuscular junction blockade, rhabdomyolysis, cachectic myopathy, and 
rarely GBS. Consequently, ICU patients who acquire these disorders have significantly prolonged ICU 
stays and increased length of hospital stay overall.  
Loss of myosin fibers results in CIM and the only certain risk factor established thus far is 
intravenous glucocorticoid treatment [8]. CIP is a common complication of severe sepsis and the 
implicated pathogenetic mechanism is injury to the microcirculation of distal nerves, causing ischemia 
and axonal degeneration [9]. Prolonged neuromuscular junction blockade occurs in patients with 
hepatic or renal insufficiency that recieved treatment with paralytic agents. Cachectic myopathy is due 
to protein catabolism and disuse, while infection and medications can induce rhabdomyolysis.  
Obviously, the diagnosis of GBS, as the most scarce cause of the new onset flaccid paralysis 
in the ICU setting requires a high index of suspicion. However, recognition of this syndrome is of vital 
importance, since unlike other conditions that induce flaccid paralysis in the ICU it has effective 
treatment with either IVIG or PE. Furthermore, if this disorder is not identified promptly and the 
treatment is delayed possible detrimental consequences such as permanent neurological deficits and 
even death can occur. 
Despite only limited experience, it is mandatory to perform electrophysiological studies, 
lumbar puncture and anti-ganglioside antibody assay in all critically ill patients with the new onset 
flaccid tetraplegia, especially if pandemic influenza A or some other infection was the reason for the 
ICU admission.  
 10
Risk factors for other causes of ICU neuromuscular weakness are usually present in the ICU 
setting and should not be the reason for reluctance in active quest for GBS. Once the diagnosis of GBS 
is established or suspected the treatment with PE or IVIG should commence. Our patient responded to 
the PE treatment and since the experience with this infectious agent as antecedent agent of the AMAN 
variant of the GBS is absent we suggest PE to be the first line of treatment.     
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